I believe the gist of it is: FDA is willing to accept new potency data generated to pave the way for FDA to consider pH 3 trial MAB-GVHD001 gor paediatrics as adequate study. I think (a) a few months is quite a good time frame for a potentially significant outcome.
Re adults, a 12 month controlled single arm is also quite a reasonable outcome and given the data and evidence already, that should be a matter of ticking the box ... something FDA likes.
So, much better than we could have potentially ntcipated.
Ann: Mesoblast Type A Meeting with FDA, page-8
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.020(1.87%) |
Mkt cap ! $1.227B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.07 | $1.420M | 1.310M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 30842 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 63137 | 19 |
View Market Depth
| Last trade - 12.09pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.020 ( 2.12 %) |
||||
| Open | High | Low | Volume | ||
| $1.08 | $1.10 | $1.07 | 245064 | ||
| Last updated 12.32pm 13/06/2024 ? | |||||
| MSB (ASX) Chart |